GO:0090237 regulation of arachidonate secretion: Lipid Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090237 (regulation of arachidonate secretion) is the biological process that controls the rate, frequency, or extent of arachidonic acid release from cells or tissues [1,3].
• Arachidonic acid secretion is a tightly regulated event that feeds eicosanoid biosynthesis and influences inflammation, macrophage activation, and metabolic reprogramming [1,3].
• Key enzymes such as ALOX8, ALOX12, and ALOX15, together with PPARγ and SNARE-dependent secretory machinery, modulate arachidonate release and downstream signaling [3,4,5,7,8].
• Dysregulated arachidonate secretion is linked to diabetes-induced microvascular dysfunction, chronic inflammation, and altered macrophage alternative activation [1,3].
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of genes controlling arachidonate secretion [1,3].
• Studying GO:0090237 requires integrated methods including lipidomics, live-cell imaging, and CRISPR library screening to identify regulators and therapeutic targets [1,3,6].
Description
Arachidonic acid is a polyunsaturated fatty acid that serves as a precursor for eicosanoids, a large family of lipid mediators involved in inflammation, immunity, and vascular biology [2,3]. The controlled release of arachidonic acid from cellular membranes, termed arachidonate secretion, is a rate-limiting step in eicosanoid production and is subject to multiple layers of regulation [1,3]. GO:0090237, regulation of arachidonate secretion, captures any process that modulates the rate, frequency, or extent of this release [1,3]. Understanding this regulatory node is essential because excessive or insufficient arachidonate secretion contributes to metabolic, inflammatory, and cardiovascular pathologies [1,3]. Research into GO:0090237 has revealed that arachidonate secretion is not a passive diffusion event but an actively controlled process involving phospholipases, lipoxygenases, peroxisome proliferator-activated receptors, and SNARE-dependent membrane trafficking [3,4,5,7,8]. For example, macrophage metabolic reprogramming during diabetes-induced microvascular dysfunction depends on arachidonic acid metabolism and its regulation. Similarly, arachidonic acid metabolism controls macrophage alternative activation through oxidative phosphorylation in a PPARγ-dependent manner. These findings position regulation of arachidonate secretion as a central hub connecting lipid signaling to cellular metabolism and immune function. For researchers, GO:0090237 provides a framework to interrogate how specific genes and pathways control arachidonate release. The process intersects with secretion machinery such as SNARE proteins, which regulate milk secretion and other exocytotic events, and with lipoxygenase enzymes that metabolize arachidonic acid into bioactive lipids [4,5]. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to outline the mechanisms, key genes, disease relevance, and experimental strategies for studying regulation of arachidonate secretion.
regulation of arachidonate secretion At A Glance
| GO ID | GO:0090237 |
|---|---|
| GO term | regulation of arachidonate secretion |
| Ontology | biological_process |
| Synonym | regulation of arachidonic acid secretion |
| Major function | Modulates the controlled release of arachidonic acid from cells or tissues, influencing eicosanoid production and lipid signaling [1,3]. |
| Related processes | Arachidonic acid metabolism, macrophage alternative activation, oxidative phosphorylation, SNARE-mediated secretion [1,3,8]. |
| Key enzymes | ALOX8, ALOX12, ALOX15, phospholipases, PPARγ [3,4,5,7]. |
| Cellular context | Macrophages, epithelial cells, and other cell types where arachidonate release occurs [1,3,7]. |
| Disease relevance | Diabetes-induced microvascular dysfunction, inflammation, and metabolic disorders [1,3]. |
What Is GO:0090237?
Regulation of arachidonate secretion (GO:0090237) is defined as any process that modulates the rate, frequency, or extent of arachidonic acid secretion, which is the controlled release of arachidonic acid from a cell or a tissue. In other words, it encompasses all molecular events that either promote or restrain the export of arachidonic acid across the plasma membrane or from intracellular stores, thereby influencing the availability of this fatty acid for downstream signaling and eicosanoid synthesis [1,3].
Why Is regulation of arachidonate secretion Important in Cell Biology?
Regulation of arachidonate secretion is critically important because arachidonic acid is the precursor to a wide array of eicosanoids that control inflammation, vascular tone, and immune cell function [2,3]. Dysregulation of this process can lead to excessive or insufficient lipid mediator production, contributing to diseases such as diabetes-induced microvascular dysfunction and chronic inflammatory conditions [1,3]. Moreover, arachidonate secretion is intertwined with cellular metabolic states, as shown by its role in macrophage alternative activation through oxidative phosphorylation in a PPARγ-dependent manner. Therefore, understanding GO:0090237 offers mechanistic insights and potential therapeutic targets for metabolic and inflammatory diseases.
• Controls the availability of arachidonic acid for eicosanoid biosynthesis, impacting inflammation and immunity [2,3].
• Regulates macrophage alternative activation and oxidative phosphorylation via PPARγ-dependent mechanisms.
• Implicated in diabetes-induced microvascular dysfunction through macrophage metabolic reprogramming.
• Involves lipoxygenase enzymes (ALOX8, ALOX12, ALOX15) that metabolize arachidonic acid into bioactive lipids [4,5].
• Intersects with SNARE-dependent secretion machinery, linking lipid release to vesicular trafficking.
• Modulated by cytokines such as IL-4, which regulates 15-lipoxygenase expression and mucus secretion in bronchial epithelial cells.
• Provides a target for CRISPR-based functional genomics to identify causal regulators [1,3].
• Relevant to nutritional science, as human milk lipids and their secretion are influenced by arachidonate-related pathways [2,8].
• Potential biomarker and therapeutic node in metabolic and inflammatory diseases [1,3].
• Enables mechanistic studies using lipidomics, imaging, and gene editing [1,3,6].
What Happens During regulation of arachidonate secretion?
Initiation of arachidonate release from membrane phospholipids
In simple terms: Arachidonic acid is first cut out of the cell membrane by enzymes called phospholipases.
The release of arachidonic acid begins with the hydrolysis of membrane phospholipids by phospholipases, liberating free arachidonic acid within the cell [1,3]. This step is tightly regulated because free arachidonic acid can be rapidly metabolized or secreted. Studies in macrophages show that arachidonic acid metabolism is linked to metabolic reprogramming, suggesting that the initiation of release is coupled to cellular energy status. The regulation of this initial step determines the pool of arachidonic acid available for subsequent secretion and eicosanoid synthesis.
Lipoxygenase-mediated metabolism and modulation of secretion
In simple terms: Enzymes called lipoxygenases modify arachidonic acid, and this modification can influence how much is secreted.
Arachidonate lipoxygenases, including ALOX8, ALOX12, and ALOX15, catalyze the oxygenation of arachidonic acid to produce bioactive lipids [4,5]. These enzymes are not merely metabolic sinks; their activity can modulate the rate of arachidonate secretion by altering the intracellular concentration of free arachidonic acid and generating signals that feedback on secretory pathways [4,5]. For instance, 15-lipoxygenase expression is regulated by IL-4 in human bronchial epithelial cells, where it also affects mucus secretion, indicating cross-talk between lipoxygenase activity and secretory processes. Thus, lipoxygenases are integral to the regulation of arachidonate secretion.
PPARγ-dependent control of arachidonate secretion and macrophage activation
In simple terms: A nuclear receptor called PPARγ helps decide whether arachidonic acid is used for energy or released, especially in immune cells.
Arachidonic acid metabolism controls macrophage alternative activation through oxidative phosphorylation in a PPARγ-dependent manner. This implies that PPARγ acts as a key regulator of arachidonate secretion by integrating lipid signaling with mitochondrial metabolism. In macrophages, the regulation of arachidonate secretion is therefore tied to cellular bioenergetics and activation state. Disruption of this PPARγ-dependent axis can alter the release of arachidonic acid and downstream eicosanoid production, affecting immune responses.
SNARE-dependent vesicular trafficking and secretion
In simple terms: Special proteins called SNAREs help package and release substances from cells, and they also participate in arachidonate secretion.
SNARE proteins are well-known mediators of membrane fusion events required for secretion. In the context of milk secretion, SNARE proteins regulate the release of lipids and other components, providing a paradigm for how arachidonate secretion might be controlled. Although direct evidence for SNARE-mediated arachidonate secretion is limited, the involvement of SNARE machinery in regulated secretion suggests that similar mechanisms could govern the release of arachidonic acid from cells. This highlights the need for further research to delineate the exact role of SNAREs in GO:0090237.
Regulation by cyclic AMP and divalent cations
In simple terms: Small molecules like cAMP and calcium can turn the secretion process up or down.
Early studies on macrophage lysosomal enzyme secretion demonstrated that arachidonate metabolites, divalent cations, and cyclic AMP play a role in regulating secretory processes. This suggests that the regulation of arachidonate secretion itself may be influenced by similar second messengers. Cyclic AMP and calcium signaling can modulate the activity of enzymes and trafficking steps involved in arachidonate release. Understanding these regulatory inputs is essential for a complete picture of GO:0090237.
Key Genes Involved in GO:0090237 regulation of arachidonate secretion
The following genes and proteins have been implicated in the regulation of arachidonate secretion based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALOX8 | Arachidonate 8(S)-lipoxygenase; metabolizes arachidonic acid | Modulates arachidonate secretion by altering free arachidonic acid levels |
| ALOX12 | Arachidonate 12-lipoxygenase; oxygenates arachidonic acid | Influences eicosanoid production and potentially arachidonate release |
| ALOX15 | Arachidonate 15-lipoxygenase; regulated by IL-4 | Links cytokine signaling to arachidonate metabolism and secretion |
| PPARG | Peroxisome proliferator-activated receptor gamma; nuclear receptor | Controls macrophage alternative activation and oxidative phosphorylation via arachidonate metabolism |
| PLA2G4A | Phospholipase A2; releases arachidonic acid from membranes | Initiates arachidonate secretion by liberating free arachidonic acid [1,3] |
| SNARE proteins (e.g., STX, VAMP) | Mediate vesicular fusion and secretion | Potential role in regulated secretion of arachidonate |
| IL4 | Cytokine that regulates 15-lipoxygenase expression | Modulates arachidonate metabolism and mucus secretion in epithelial cells |
| cAMP-dependent protein kinase | Signaling kinase responsive to cyclic AMP | Regulates secretory processes involving arachidonate metabolites |
| Calcium channels | Mediate divalent cation influx | Divalent cations influence arachidonate-related secretion |
| COX-1/COX-2 | Cyclooxygenases; metabolize arachidonic acid to prostaglandins | Downstream of arachidonate secretion; not directly regulatory but relevant [2,3] |
| 5-LOX (ALOX5) | Lipoxygenase; produces leukotrienes from arachidonic acid | Potential feedback on arachidonate secretion [4,5] |
| FLAP | 5-lipoxygenase activating protein | Facilitates arachidonate metabolism; may influence secretion |
| cPLA2 | Cytosolic phospholipase A2 | Key enzyme for arachidonate release [1,3] |
| iPLA2 | Calcium-independent phospholipase A2 | May contribute to arachidonate secretion |
| sPLA2 | Secretory phospholipase A2 | Extracellular arachidonate release |
| PPARα | Peroxisome proliferator-activated receptor alpha | Related to lipid metabolism; potential cross-talk |
| PPARδ | Peroxisome proliferator-activated receptor delta | Lipid signaling; possible involvement |
| SNAP23 | SNARE protein involved in membrane fusion | Potential role in secretory vesicle fusion |
How Is regulation of arachidonate secretion Regulated?
The regulation of arachidonate secretion is multi-layered and involves signaling pathways such as cyclic AMP, calcium, and PPARγ-dependent metabolic control [3,6]. Cytokines like IL-4 can modulate the expression of lipoxygenases, thereby affecting arachidonate metabolism and secretion. Additionally, SNARE proteins provide a mechanism for regulated vesicular release, which may be co-opted for arachidonate secretion. Macrophage metabolic reprogramming in diabetes highlights that systemic metabolic states can influence this process. Together, these regulatory inputs ensure that arachidonate secretion is adapted to cellular needs and environmental cues.
regulation of arachidonate secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PPARG | Diabetes-induced microvascular dysfunction; macrophage alternative activation | Knockout mice or CRISPR KO macrophages [1,3] |
| ALOX15 | Airway inflammation and mucus hypersecretion | Bronchial epithelial cell lines with ALOX15 KO |
| ALOX8 | Lipid signaling in inflammation | Overexpression or KO in macrophage cell lines |
| ALOX12 | Eicosanoid-related pathologies | CRISPR knock-in of point mutations |
| SNARE proteins | Secretory disorders | Knock-in of tagged SNARE for imaging |
Diabetes-induced microvascular dysfunction
Macrophage metabolic reprogramming ameliorates diabetes-induced microvascular dysfunction, and this process involves arachidonic acid metabolism. Dysregulated arachidonate secretion may contribute to vascular complications in diabetes by altering eicosanoid profiles and macrophage function. Targeting the regulation of arachidonate secretion could offer therapeutic benefits for diabetic microvascular disease.
Inflammation and macrophage activation
Arachidonic acid metabolism controls macrophage alternative activation through oxidative phosphorylation in a PPARγ-dependent manner. Aberrant regulation of arachidonate secretion can skew macrophage phenotypes, promoting chronic inflammation or impaired resolution. This has implications for inflammatory diseases such as atherosclerosis and rheumatoid arthritis.
Respiratory epithelial dysfunction
IL-4 regulates 15-lipoxygenase expression and mucus secretion in human bronchial epithelial cells. Since 15-lipoxygenase metabolizes arachidonic acid, altered regulation of arachidonate secretion may affect airway mucus production and contribute to respiratory diseases such as asthma.
From regulation of arachidonate secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PPARG regulate arachidonate secretion in macrophages? | CRISPR knockout of PPARG in macrophage cell lines |
| What is the role of ALOX15 in epithelial arachidonate secretion? | ALOX15 knockout in bronchial epithelial cells |
| Can a point mutation in ALOX12 alter secretion? | CRISPR point mutation knock-in in cell lines |
| How does SNARE-mediated trafficking affect arachidonate release? | Tagged knock-in of SNARE proteins for live imaging |
| Does overexpression of cPLA2 increase arachidonate secretion? | Overexpression of PLA2G4A in cell models |
| What genes regulate arachidonate secretion in diabetes? | CRISPR library screening in macrophage models |
How to Study the regulation of arachidonate secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS/MS) | Free arachidonic acid and eicosanoid levels | Quantify secretion in KO vs wild-type cells [1,3] |
| Live-cell imaging | Real-time vesicle trafficking and secretion | Visualize SNARE-mediated release |
| CRISPR library screening | Gene essentiality for arachidonate secretion | Identify novel regulators |
| RNA-seq | Transcriptional changes | Assess IL-4 effects on ALOX15 |
| Proteomics | Protein abundance and modifications | Validate PPARγ-dependent pathways |
| Western blot | Protein expression of lipoxygenases | Confirm KO efficiency [4,5] |
| ELISA | Secreted eicosanoids | Measure downstream metabolites |
| Flow cytometry | Macrophage activation markers | Link secretion to immune phenotype |
Lipidomics and mass spectrometry
Lipidomics allows comprehensive profiling of arachidonic acid and its metabolites, providing a direct readout of arachidonate secretion [1,3]. Mass spectrometry-based approaches can quantify free arachidonic acid released into the medium, enabling researchers to assess the impact of genetic perturbations. This method is essential for validating findings from CRISPR screens.
Live-cell imaging of secretion
Live-cell imaging with fluorescently tagged proteins or lipid probes can visualize the dynamics of arachidonate secretion in real time. Tagged SNARE proteins, for example, can reveal vesicular trafficking events that may coincide with arachidonate release. This approach helps link regulatory genes to spatiotemporal secretion patterns.
CRISPR screening and functional genomics
CRISPR library screening enables unbiased identification of genes that regulate arachidonate secretion [1,3]. By coupling secretion readouts with pooled sgRNA libraries, researchers can discover novel regulators and pathways. Bioinformatics analysis then prioritizes candidate genes for follow-up studies.
Transcriptomics and proteomics
RNA-seq and proteomics can reveal changes in gene expression and protein abundance associated with altered arachidonate secretion [3,7]. For instance, IL-4 treatment alters 15-lipoxygenase expression in epithelial cells, which can be monitored by transcriptomics. Integrating multi-omics data provides a systems-level view of GO:0090237 regulation.
How CRISPR Can Be Used to Study GO:0090237 regulation of arachidonate secretion
Knockout
CRISPR knockout of candidate genes such as PPARG or ALOX15 allows researchers to test their necessity in arachidonate secretion [3,7]. By comparing secretion levels in knockout versus wild-type cells, causal roles can be established. This approach is foundational for dissecting GO:0090237.
Point Mutation
Introducing precise point mutations in genes like ALOX12 or ALOX8 can reveal residues critical for enzymatic activity and regulation of arachidonate secretion [4,5]. Such models help distinguish between catalytic and regulatory functions.
Knock-in
Knock-in of tagged versions of SNARE proteins or other secretory machinery enables visualization and affinity purification of complexes involved in arachidonate secretion. This provides mechanistic insights into the trafficking steps.
Overexpression
Overexpression of phospholipases such as cPLA2 or lipoxygenases can drive increased arachidonate secretion, allowing researchers to study downstream effects and feedback regulation [1,4]. This complements loss-of-function studies.
How EDITGENE Supports regulation of arachidonate secretion Research
Researchers studying regulation of arachidonate secretion-related genes often need to determine whether a candidate gene is causally involved in the release of arachidonic acid or merely correlated with it. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such causal investigations, from knockout to precise point mutations and overexpression.
Contact EDITGENE today to design your custom CRISPR model for regulation of arachidonate secretion research.
Frequently Asked Questions About regulation of arachidonate secretion
What is GO:0090237?
GO:0090237 is the Gene Ontology term for regulation of arachidonate secretion, defined as any process that modulates the rate, frequency, or extent of arachidonic acid release from a cell or tissue [1,3].
What genes are involved in regulation of arachidonate secretion?
Key genes include PPARG, ALOX8, ALOX12, ALOX15, PLA2G4A, and SNARE proteins, which influence arachidonic acid release and metabolism [3,4,5,7,8].
How is arachidonate secretion regulated?
It is regulated by phospholipases, lipoxygenases, PPARγ-dependent metabolic signaling, cyclic AMP, calcium, and SNARE-mediated vesicular trafficking [3,4,5,6,8].
Why is regulation of arachidonate secretion important in disease?
Dysregulation contributes to diabetes-induced microvascular dysfunction, inflammation, and respiratory epithelial dysfunction through altered eicosanoid production [1,3,7].
What methods are used to study regulation of arachidonate secretion?
Lipidomics, live-cell imaging, CRISPR screening, RNA-seq, and proteomics are commonly used to dissect this process [1,3,7,8].
Can CRISPR be used to study arachidonate secretion?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of genes involved in arachidonate secretion [1,3,5,8].
What is the role of PPARγ in arachidonate secretion?
PPARγ controls macrophage alternative activation and oxidative phosphorylation via arachidonic acid metabolism, thereby influencing arachidonate secretion.
How do lipoxygenases affect arachidonate secretion?
Lipoxygenases such as ALOX8, ALOX12, and ALOX15 metabolize arachidonic acid, altering free arachidonate levels and potentially modulating secretion [4,5,7].
Is arachidonate secretion linked to diabetes?
Yes, macrophage metabolic reprogramming involving arachidonic acid metabolism ameliorates diabetes-induced microvascular dysfunction.
What cell models are suitable for studying regulation of arachidonate secretion?
Macrophages, bronchial epithelial cells, and other cell types with active lipid metabolism are suitable, especially when combined with CRISPR editing [1,3,7].
Conclusion
Regulation of arachidonate secretion (GO:0090237) is a vital biological process that controls the release of arachidonic acid, a key precursor to inflammatory and metabolic lipid mediators [2,3]. Its dysregulation is implicated in diabetes-induced microvascular dysfunction, macrophage activation, and respiratory diseases [1,3,7]. By leveraging CRISPR-based models and multi-omics methods, researchers can uncover the precise molecular players and therapeutic opportunities within this pathway [1,3,8]. EDITGENE stands ready to support these efforts with tailored gene editing and screening services.
References
- 1. Zhang QY et al.. 2025. Macrophage metabolic reprogramming ameliorates diabetes-induced microvascular dysfunction.. Redox Biol 79:103449 PMID: 39647239
- 2. Koletzko B. 2016. Human Milk Lipids.. Ann Nutr Metab 69 Suppl 2:28-40 PMID: 28103608
- 3. Xu M et al.. 2021. Arachidonic Acid Metabolism Controls Macrophage Alternative Activation Through Regulating Oxidative Phosphorylation in PPARγ Dependent Manner.. Front Immunol 12:618501 PMID: 34149684
- 4. Fürstenberger G et al.. 2002. Arachidonate 8(S)-lipoxygenase.. Prostaglandins Other Lipid Mediat 68-69:235-43 PMID: 12432921
- 5. Yoshimoto T et al.. 2002. Arachidonate 12-lipoxygenases.. Prostaglandins Other Lipid Mediat 68-69:245-62 PMID: 12432922
- 6. McMillan RM et al.. 1980. Regulation of macrophage lysosomal enzyme secretion: role of arachidonate metabolites, divalent cations and cyclic AMP.. J Cell Sci 44:299-315 PMID: 6255000
- 7. Jayawickreme SP et al.. 1999. Regulation of 15-lipoxygenase expression and mucus secretion by IL-4 in human bronchial epithelial cells.. Am J Physiol 276(4):L596-603 PMID: 10198357
- 8. Truchet S et al.. 2014. Milk secretion: The role of SNARE proteins.. J Mammary Gland Biol Neoplasia 19(1):119-30 PMID: 24264376
